证券代码：603222 证券简称：济民健康 公告编号：2026-008 关于公司股东协议转让股份暨股东权益变动 的提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 济民健康管理股份有限公司（以下简称"公司"或"济民健康"）的控股 股东双鸽集团有限公司（以下简称"双鸽集团"）于 2026 年 3 月 6 日与湖北长 河壹号科技合伙企业（有限合伙）（以下简称"长河壹号"）签订了《关于 济民健康管理股份有限公司之股份转让协议》（以下简称"股份转让协议"）， 通过协议转让的方式，向长河壹号转让其所持有济民健康无限售流通股 26,254,600 股股份，占济民健康总股本的 5%，转让价格为 7.72 元/股，转让 对价 202,685,512 元人民币。 ● 本次股份转让的双方将严格遵守相关法律法规和规范性文件等的有关规 定；受让方长河壹号承诺自标的股份完成过户登记之日起 12 个月内不转让其持 有的目标公司股份。 ● 本次交易不触及要约收购，不会导致公司控股股东、实际控制人发生变更， 亦不会对公 ...

Group 1: Share Buyback Announcement - The company has approved a share buyback plan using its own funds and bank loans, with a maximum price of RMB 10 per share and a total amount between RMB 100 million and RMB 200 million, to be executed within 12 months [2] - As of February 27, 2026, the company has repurchased 10,626,840 shares, representing 2.02% of the total share capital, with a total expenditure of RMB 90,962,358.7, excluding transaction fees [3] - In February 2026 alone, the company repurchased 5,286,560 shares, accounting for 1.01% of the total share capital, with a total payment of RMB 48,876,806.4, excluding transaction fees [3] Group 2: Guarantee for Subsidiary Financing - The company has provided a guarantee for its wholly-owned subsidiary, Jumin Biotechnology Co., Ltd., for a loan application to a bank, with a maximum guarantee amount of RMB 55 million, which is 3.71% of the company's latest audited net assets [7][8] - The board of directors has approved a total guarantee limit of up to RMB 600 million for the subsidiary's financing needs, which includes various forms of guarantees [9] - The guarantee is deemed necessary to support the subsidiary's business expansion and financing needs, with minimal risk to the company [13]

Group 1 - The core point of the article is that Jimin Health announced a share buyback program, having repurchased a total of 10,626,840 shares, which represents 2.02% of the company's total share capital as of February 27, 2026 [2] - In February 2026 alone, the company repurchased 5,286,560 shares, accounting for 1.01% of the total share capital [2]

Summary of Key Points Core Viewpoint - Jimin Health (603222.SH) has announced a share buyback program, indicating a strategic move to enhance shareholder value and confidence in the company's future prospects [1] Group 1: Share Buyback Details - The company has repurchased a total of 10.6268 million shares, which represents 2.02% of its total share capital [1] - The highest purchase price during the buyback was 9.75 yuan per share, while the lowest was 5.87 yuan per share [1] - The total amount spent on the buyback, excluding transaction fees, is 90.9624 million yuan [1]

证券代码：603222 证券简称：济民健康 公告编号：2026-007 济民健康管理股份有限公司 关于为控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | | 累计担保情况 | 对外担保逾期的累计金额（万元） | 无 | | --- | --- | | 截至本公告日上市公司及其控股 | 32,219.00 | | 子公司对外担保总额（万元） | | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 21.76 | | 特别风险提示（如有请勾选） | □担保金额（含本次）超过上市公司最近一 | | | 期经审计净资产 50% | | | □对外担保总额（含本次）超过上市公司最 | | | 近一期经审计净资产 100% | | | □对合并报表外单位担保总额（含本次）达 | | | 到或超过最近一期经审计净资产 30% | | | □本次对资产负债率超过 70%的单位提供担 | | | 保 | | 其他风险提示（如有） | 无 | 一、担保情况概述 ...

| 回购方案首次披露日 | 2025/3/29 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 10,000万元~20,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 1,062.68万股 | | 累计已回购股数占总股本比例 | 2.02% | | 累计已回购金额 | 9,096.24万元 | | 实际回购价格区间 | 5.87元/股~9.75元/股 | 一、回购股份的基本情况 济民健康管理股份有限公司(以下简称"公司")于 2025 年 3 月 28 日召开第 五届董事会第十七次会议，审议通过了《关于以集中竞价交易方式回购股份方案 的议案》，同意公司使用自有资金及金融机构借款以集中竞价交易方式回购公司股 份，回购价格不超过人民币 10 元/股（含）；回购资金总额不低于人民币 10,000 万元（含）且不超过人民币 20,000 万元（含）；回购期限为自董事会审议通过回 购方案之日起不超过 12 个月。具体内容 ...

Group 1 - The core viewpoint of the news is that Jimin Health has experienced fluctuations in its stock performance and financial metrics, indicating potential investment opportunities and risks [1][2]. - On February 25, Jimin Health's stock rose by 1.68%, with a trading volume of 75.77 million yuan. The net financing purchase was 211,300 yuan, with a total financing and margin balance of 169 million yuan [1]. - The financing balance of Jimin Health is 169 million yuan, accounting for 3.55% of its market capitalization, which is below the 20th percentile level over the past year, indicating a low financing level [1]. - In terms of short selling, Jimin Health had no shares repaid on February 25, with 300 shares sold short, amounting to 2,721 yuan. The short selling balance is 8,070 yuan, which is above the 80th percentile level over the past year, indicating a high level of short selling [1]. Group 2 - As of September 30, the number of shareholders of Jimin Health increased by 107% to 58,100, while the average circulating shares per person decreased by 51.69% to 9,035 shares [2]. - For the period from January to September 2025, Jimin Health reported a revenue of 545 million yuan, a year-on-year decrease of 20.21%. The net profit attributable to the parent company was -77.15 million yuan, a significant year-on-year decrease of 371.51% [2]. - Since its A-share listing, Jimin Health has distributed a total of 127 million yuan in dividends, with 10.74 million yuan distributed in the last three years [3].

Core Viewpoint - The medical device sector experienced a rise of 1.42% on February 3, with Huakang Clean leading the gains, while the overall market indices also showed positive performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4067.74, up by 1.29% [1]. - The Shenzhen Component Index closed at 14127.1, up by 2.19% [1]. Group 2: Top Gainers in Medical Device Sector - Huakang Clean (301235) closed at 53.83, with a gain of 9.86% and a trading volume of 114,200 shares, amounting to a transaction value of 610 million yuan [1]. - Baocait (300246) closed at 13.15, up by 7.96% with a trading volume of 178,500 shares, totaling 229 million yuan [1]. - Yirui Technology (688301) closed at 119.24, increasing by 7.10% with a trading volume of 41,000 shares, resulting in a transaction value of 477 million yuan [1]. - Hualan Co. (301093) closed at 86.08, up by 6.45% with a trading volume of 60,900 shares, totaling 482 million yuan [1]. - Tianzhihang (688277) closed at 24.18, increasing by 6.10% with a trading volume of 159,300 shares, amounting to 379 million yuan [1]. Group 3: Market Outflows and Inflows - The medical device sector saw a net outflow of 253 million yuan from institutional investors and a net outflow of 112 million yuan from speculative funds, while retail investors had a net inflow of 365 million yuan [2]. - The detailed fund flow for individual stocks indicates varying levels of net inflow and outflow among different companies [3].

Group 1 - The company has appointed Tianjian Accounting Firm as the auditor for its 2025 financial statements and internal control audits [1][2] - The signing auditors have changed due to internal adjustments at Tianjian, with Wang Chao replacing Peng Haowei [2] - Wang Chao has been engaged in auditing since 2017 and became a certified public accountant in April 2021 [3] Group 2 - Wang Chao has no criminal or administrative penalties in the past three years [4] - The new signing auditor meets the independence requirements as per the Code of Ethics for Chinese Certified Public Accountants [5] - The change in signing auditors will not affect the audit work for the company's 2025 financial statements and internal controls [6] Group 3 - The company has initiated a share repurchase program, with a total repurchase amount between RMB 100 million and RMB 200 million [9] - As of January 30, 2026, the company has repurchased 5,340,280 shares, accounting for 1.02% of the total share capital, with a total expenditure of approximately RMB 42.09 million [9][10] - In January 2026, the company repurchased 2,279,780 shares, representing 0.43% of the total share capital, with a total expenditure of approximately RMB 20.10 million [10]

Group 1 - The company Jimin Health announced a change in its signing registered accountants to Lai Xingkai and Wang Chao [2]